Dasatinib Active Not Recruiting Phase 2 Trials for Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia / Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / chronic Chronic myelogenous leukemia Treatment

IndicationsStatusPurposePhase
Active Not RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00254423Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia